| Info Sheets |
| | | | | | | | | | | | | | | | | | | | | | | | |
| Out- side |
| | | | |
|
| | | | |
Result : Searchterm 'B0' found in 1 term [] and 43 definitions []
| previous 11 - 15 (of 44) nextResult Pages : [1] [2 3 4 5 6 7 8 9] | | | | Searchterm 'B0' was also found in the following services: | | | | |
| | |
| |
|
Drug Information and Specification
T1, Predominantly positive enhancement
PHARMACOKINETIC
Intravascular, extracellular, renal excretion
DOSAGE
0.1 mmol/kg / 0.2mL/kg
PREPARATION
Finished product
INDICATION
Neuro/whole body
DEVELOPMENT STAGE
For sale
PRESENTATION
Vials of 5, 10, 15, 20mL Pre-filled syringes of 15 and 20 mL
DO NOT RELY ON THE INFORMATION PROVIDED HERE, THEY ARE NOT A SUBSTITUTE FOR THE ACCOMPANYING
PACKAGE INSERT!
Distribution Information
TERRITORY
TRADE NAME
DEVELOPMENT STAGE
DISTRIBUTOR
France, Switzerland
Artirem®
for sale
| | | | | Further Reading: | | Basics:
|
|
News & More:
| |
| |
| | | | | |
| |
|
Some dyamides are under preclinical development as intravascular MRI contrast agents for blood flow perfusion.
Short name: Dy-DTPA-BMA, generic name: Sprodyamide, central moiety: Dy2+, contrast effect: T2*enhanced, relaxivity: r1=3.4, r2=3.8, B0=0.47,
Short name: Dy-DTPA, central moiety: Dy2+, contrast effect: T2*enhanced,
Short name: Albumin-(Dy-DTPA)x, central moiety: Dy2+, contrast effect: T2*enhanced.
| | | | | Further Reading: | Basics:
|
|
| |
| | | | | |
| |
|
A brand name for ferumoxide (same as Feridex®)
Endoremâ„¢ is a black to reddish-brown aqueous colloid of superparamagnetic iron oxide associated with dextran for intravenous administration as a MRI contrast medium for the detection of liver lesions that are associated with an alteration in the RES.
Endoremâ„¢ is taken up by macrophages, found only in healthy liver cells but not in most tumors. Tissues such as metastases, primary liver cancer, cysts and various benign tumors, adenomas and hyperplasia retain their native signal intensity, so the contrast between normal and abnormal tissue is increased.
See also Ferumoxide.
Drug Information and Specification
T2, predominantly negative enhancement
r1=40.0, r2=160, B0=0.47T
PHARMACOKINETIC
RES-directed
CONCENTRATION
11.2mg Fe/ml
PREPARATION
Suspend in an isotonic glucose solution
DEVELOPMENT STAGE
For sale
PRESENTATION
Ampoule of 8 mL
DO NOT RELY ON THE INFORMATION PROVIDED HERE, THEY ARE NOT A SUBSTITUTE FOR THE ACCOMPANYING
PACKAGE INSERT!
Distribution Information
TERRITORY
TRADE NAME
DEVELOPMENT STAGE
DISTRIBUTOR
EU Brazil
Endorem™
for sale
| | | | • View the DATABASE results for 'Endorem™' (5).
| | | | Further Reading: | News & More:
|
|
| |
| | | Searchterm 'B0' was also found in the following services: | | | | |
| | |
| |
|
A brand name for ferumoxide (same as Endorem™)
Feridex® is a sterile aqueous colloid of superparamagnetic iron oxide associated with dextran for intravenous administration as a MRI contrast medium for the detection of liver lesions that are associated with an alteration in the RES.
Feridex® is taken up by macrophages, found only in healthy liver cells but not in most tumors. Tissues such as metastases, primary liver cancer, cysts and various benign tumors, adenomas and hyperplasia retain their native signal intensity, so the contrast between normal and abnormal tissue is increased.
Feridex® is a black to reddish-brown aqueous colloid.
See also Ferumoxide. In November 2008, AMAG Pharmaceuticals, Inc. decided to discontinue the manufacturing of Feridex.
Drug Information and Specification
T2, predominantly negative enhancement
r1=40.0, r2=160, B0=0.47T
PHARMACOKINETIC
RES-directed
CONCENTRATION
11.2mg Fe/ml
PREPARATION
Suspend in an isotonic glucose solution
DEVELOPMENT STAGE
For sale
PRESENTATION
Ampoule of 8 mL
DO NOT RELY ON THE INFORMATION PROVIDED HERE, THEY ARE NOT A SUBSTITUTE FOR THE ACCOMPANYING
PACKAGE INSERT!
Distribution Information
TERRITORY
TRADE NAME
DEVELOPMENT STAGE
DISTRIBUTOR
| | | | • View the DATABASE results for 'Feridex®' (9).
| | | | Further Reading: | Basics:
|
|
News & More:
| |
| |
| | | | | |
| |
|
Quick Overview
A disturbance of the field homogeneity, because of magnetic material (inside or outside the patient), technical problems or scanning at the edge of the field.
When images were obtained in a progression from the center to the edge of the coil, the homogeneity of the field observed by the imaged volume, changes when the distance from the center of the volume increase.
The same problem appears by scanning at a distance from the isocenter in left-right direction or too large field of view.
There are different types of bad image quality, the images are noisy, distorted or the fat suppression doesn't work because of badly set shim currents.
E.g. by using an IR sequence, changes in the T1 recovery rates of the tissues are involved. The inversion time at the center of the imaged volume is appropriate to suppress fat, but at the edge of the coil the same inversion time is sufficient to suppress water. Since the inversion time is not changed, the T1 recovery rates will increase.
Image Guidance
Take a smaller imaging volume (and for fat suppression a volume shimming), take care that the imaged region is at the center of the coil and that no magnetic material is inside the imaging volume. | | | | • View the DATABASE results for 'Field Inhomogeneity Artifact' (3).
| | | | Further Reading: | Basics:
|
|
| |
| | | | |
| | | |
|
| |
| Look Ups |
| |